Cited 4 times in
A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2020-07-27T16:43:26Z | - |
dc.date.available | 2020-07-27T16:43:26Z | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/178485 | - |
dc.description.abstract | Background and aim: There are limited data assessing whether patients who achieved virological suppression on lamivudine but remain hepatitis B "e" antigen-positive should be switched to a more potent antiviral with a high genetic barrier to resistance or continue with lamivudine. We compared the safety and efficacy of switching with entecavir versus continuing lamivudine. Methods: This was a Phase IV, randomized, open-label, prospective study in a tertiary care setting. Seventy-three chronic hepatitis B patients who achieved virological suppression on lamivudine (serum hepatitis B virus DNA < 60 International Unit (IU)/mL) were enrolled. Entecavir or lamivudine were administered orally for up to 96 weeks. Virologic and serologic responses were measured throughout the study. Results: A significantly higher proportion of patients in the entecavir group achieved hepatitis B virus DNA < 60 IU/mL at Weeks 48 (100% [38/38] vs 62.8% [22/35]; P < 0.001) and 96 (97.4% [37/38] vs 57.1% [20/35]; P<0.001). A greater number of patients had virologic breakthrough (Week 96 cumulative incidence 42.9% vs 2.6%; P<0.001) and genotypic lamivudine resistance (28.6% [10/35] vs 0% [0/38]; P<0.001) in the lamivudine group. No serious adverse events or laboratory abnormalities were reported. Conclusions: Even after achieving virological suppression on lamivudine therapy, the risk of emergent lamivudine resistance increases over time. Switching to entecavir resulted in a maintained virologic response and superior serologic responses versus continued lamivudine therapy. This study supports a rationale for switching to entecavir in chronic hepatitis B patients with virological suppression on lamivudine. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Jeong Heo | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Hyun Young Woo | - |
dc.contributor.googleauthor | Heon Ju Lee | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Ki Tae Yoon | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Chang Wook Kim | - |
dc.contributor.googleauthor | Hyung Hoi Kim | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Mong Cho | - |
dc.identifier.doi | 10.1111/jgh.13231 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 26572068 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.13231 | - |
dc.subject.keyword | entecavir | - |
dc.subject.keyword | hepatitis B | - |
dc.subject.keyword | lamivudine | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 31 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 865 | - |
dc.citation.endPage | 871 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.31(4) : 865-871, 2016-04 | - |
dc.identifier.rimsid | 64824 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.